<DOC>
	<DOCNO>NCT00455312</DOCNO>
	<brief_summary>Transplantation stem cell standard therapy many center around world . Previous experience stem cell transplantation therapy leukemia , lymphoma , cancer , aplastic anemia non-malignant disease , lead prolonged disease-free survival cure patient . However , high dos pre-transplant radiation chemotherapy drug use , type drug use , often cause many side effect intolerable patient . Slow recovery blood count frequent complication high dose pre-transplant regimen , result long period risk bleed infection plus long time hospital . Recent study show use low dos radiation chemotherapy ( one completely kill patient 's bone marrow cell ) blood bone marrow transplant , may better treatment high risk patient , Dyskeratosis Congenita ( DC ) Severe Aplastic Anemia ( SAA ) . These low dose transplant may result short period low blood count , blood count go low traditional pre-transplant radiation chemotherapy . Furthermore , patient Dyskeratosis Congenita SAA , stem cell transplant replace blood form cell healthy cell . It recently show healthy marrow take grow transplantation use dose chemotherapy radiation much low give patient leukemia . While high dos chemotherapy radiation may necessary get rid leukemia , may important patient Dyskeratosis Congenita SAA . The purpose research see low dose chemotherapy radiation regimen follow transplant safe effective treatment patient Dyskeratosis Congenita SAA .</brief_summary>
	<brief_title>SCT Dyskeratosis Congenita SAA</brief_title>
	<detailed_description>This open label , single arm , phase II clinical trial design evaluate safety efficacy treatment regimen . Efficacy measure long-term engraftment transplant cells.The primary endpoint neutrophil engraftment define absolute neutrophil count ( ANC ) &gt; 5 x 108/L ( first three consecutive laboratory measurement different day ) least 10 % donor cell day 100 . We evaluate proportion success ( P ) 95 % confidence interval ( CI ) entire group . The null hypothesis 90 % engraftment reject 4 patient fail engraft 15 evaluable patient . The secondary endpoint regimen related mortality , acute chronic graft-versus-host disease ( GVHD ) secondary malignancy estimate cumulative incidence treat non-event death compete risk . Survival estimate Kaplan-Meier method . Immune reconstitution summarize descriptive statistic . SAA DC arm analyze separately .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Dyskeratosis Congenita</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients dyskeratosis congenita ( DC ) severe aplastic anemia ( SAA ) 070 year age acceptable hematopoietic stem cell ( HSC ) donor HSC source HLA identical 1 antigen mismatch sibling relative eligible donate bone marrow ( BM ) , umbilical cord blood ( UCB ) mobilize peripheral blood ( PB ) cell dose meet current institutional standard . HLA identical 1 antigen mismatch unrelated donor . Two unit unrelated umbilical cord blood ( UCB ) ( ) 2 HLA antigen mismatch patient ( b ) 2 HLA antigen mismatch , ( c ) minimum cell dose ≥ 3.5 x 10^7 nucleated cells/kg optimal cell dose ≥ 5 x 10^7 nucleated cells/kg . If two unit available : single unrelated UCB unit select accord Minnesota Bone Marrow Transplant ( BMT ) program guideline Disease Characteristics DC ( follow ) : Evidence BM failure : Requirement red blood cell and/or platelet transfusion , Requirement granulocyte colonystimulating factor ( GCSF ) granulocytemacrophage colonystimulating factor ( GMCSF ) erythropoietin , Refractory cytopenia define two three : platelet &lt; 40,000/uL transfusion dependent , Absolute neutrophil count &lt; 500/uL without hematopoietic growth factor support , Hemoglobin &lt; 9g/uL transfusion dependent Diagnosis DC : A triad mucocutaneous feature : oral leukoplakia , nail dystrophy , abnormal reticular skin hyperpigmentation . Or one following : Short telomere ( research study ) , Dyskerin mutation , TERC mutation Disease Characteristics SAA ( follow ) : Evidence BM failure : Refractory cytopenia define bone marrow cellularity &lt; 2550 % ( &lt; 30 % residual hematopoietic cell ) Diagnosis SAA : Refractory cytopenia define two three : Platelets &lt; 20,000/uL transfusion dependent , Absolute neutrophil count &lt; 500/uL without hematopoietic growth factor support , Absolute reticulocyte count &lt; 20,000/uL Patients early myelodysplastic feature . Patients without clonal cytogenetic abnormality . Patient Patients one following : Decompensated congestive heart failure ; leave ventricular ejection fraction &lt; 35 % Acute hepatitis evidence moderate severe portal fibrosis cirrhosis biopsy Carbon Monoxide Diffusing Capacity ( DLCO ) &lt; 30 % predict , oxygen requirement Glomerular filtration rate ( GFR ) &lt; 30 % predict Pregnant lactate female Active serious infection whereby patient intravenous antibiotic least one week prior study entry . Any patient AIDS HIV seropositivity . If recent mold infection e.g . Aspergillus must &gt; 30 day appropriate treatment HSC transplantation infection must control clear Infectious Disease consultant . Can receive TBI due prior radiation therapy Diagnosis Fanconi anemia base diepoxybutane ( DEB ) . DC patient advance myelodysplastic syndrome ( MDS ) acute myeloid leukemia &gt; 30 blast . History non hematopoietic malignancy within 2 year except resect basal cell carcinoma treat carcinoma situ .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Dyskeratosis Congenita</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Severe Aplastic Anemia</keyword>
</DOC>